JP2011519833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519833A5 JP2011519833A5 JP2011505616A JP2011505616A JP2011519833A5 JP 2011519833 A5 JP2011519833 A5 JP 2011519833A5 JP 2011505616 A JP2011505616 A JP 2011505616A JP 2011505616 A JP2011505616 A JP 2011505616A JP 2011519833 A5 JP2011519833 A5 JP 2011519833A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- peg
- fix
- composition according
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 229920001223 polyethylene glycol Polymers 0.000 claims 11
- 102100022641 Coagulation factor IX Human genes 0.000 claims 10
- 108010076282 Factor IX Proteins 0.000 claims 8
- 229960004222 factor ix Drugs 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 208000007536 Thrombosis Diseases 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- 108010048049 Factor IXa Proteins 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 125000003827 glycol group Chemical group 0.000 claims 2
- 208000009429 hemophilia B Diseases 0.000 claims 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 claims 1
- 208000002085 hemarthrosis Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 208000007106 menorrhagia Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4754408P | 2008-04-24 | 2008-04-24 | |
| US61/047,544 | 2008-04-24 | ||
| PCT/IB2009/005763 WO2009130602A2 (en) | 2008-04-24 | 2009-04-24 | Factor ix conjugates with extended half-lives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011519833A JP2011519833A (ja) | 2011-07-14 |
| JP2011519833A5 true JP2011519833A5 (enExample) | 2012-06-14 |
Family
ID=41171051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505616A Pending JP2011519833A (ja) | 2008-04-24 | 2009-04-24 | 半減期が延長された第ｉｘ因子コンジュゲート |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20110183906A1 (enExample) |
| EP (1) | EP2280734B1 (enExample) |
| JP (1) | JP2011519833A (enExample) |
| KR (1) | KR20110016440A (enExample) |
| CN (1) | CN102046205A (enExample) |
| AU (1) | AU2009239641B2 (enExample) |
| BR (1) | BRPI0911350A2 (enExample) |
| CA (1) | CA2722169A1 (enExample) |
| CO (1) | CO6300965A2 (enExample) |
| CR (1) | CR11763A (enExample) |
| DK (1) | DK2280734T3 (enExample) |
| EC (1) | ECSP10010632A (enExample) |
| ES (1) | ES2466340T3 (enExample) |
| IL (1) | IL208908A0 (enExample) |
| MX (1) | MX2010011672A (enExample) |
| MY (1) | MY158228A (enExample) |
| NI (1) | NI201000177A (enExample) |
| NZ (1) | NZ588854A (enExample) |
| RU (1) | RU2496521C2 (enExample) |
| UA (1) | UA101497C2 (enExample) |
| WO (1) | WO2009130602A2 (enExample) |
| ZA (1) | ZA201007559B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2101821T3 (da) | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
| BR112012001814A8 (pt) | 2009-07-27 | 2018-02-06 | Baxalta GmbH | Conjugados de proteína de coagulação sanguínea |
| EP3081233B1 (en) | 2009-07-27 | 2020-12-23 | Baxalta GmbH | Glycopolysialylation of proteins other than blood coagulation proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2744370C2 (ru) | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| EP2467166A2 (en) * | 2009-08-20 | 2012-06-27 | CSL Behring GmbH | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| MX375112B (es) * | 2010-07-09 | 2025-03-06 | Biogen Hemophilia Inc | Polipéptidos de factor ix y métodos para usarlos. |
| ES2800983T3 (es) | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
| EP3412314A1 (en) * | 2011-05-27 | 2018-12-12 | Baxalta GmbH | Therapeutic proteins conjugated to polysialic acid and methods of preparing same |
| HK1200695A1 (en) * | 2012-04-16 | 2015-08-14 | Cantab Biopharmaceuticals Patents Limited | Optimised subcutaneous therapeutic agents |
| BR112014031613A2 (pt) * | 2012-06-19 | 2017-07-25 | Polytherics Ltd | processo para preparação de conjugados de anticorpos e conjugados de anticorpos |
| WO2014052490A1 (en) | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
| EA202092926A3 (ru) | 2014-03-24 | 2021-10-29 | Биовератив Терапьютикс Инк. | Лиофилизированные составы, содержащие фактор ix |
| GB2564389A (en) | 2017-07-04 | 2019-01-16 | Green Running Ltd | A system and method for utility management |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171569A (en) | 1985-03-15 | 1992-12-15 | National Research Development Corporation | Factor IX preparations uncontaminated by plasma components or pox virus |
| US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| WO2000054787A1 (en) | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| WO2001058935A2 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| KR101031206B1 (ko) * | 2002-12-31 | 2011-04-27 | 넥타르 테라퓨틱스 | 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트 |
| ATE444984T1 (de) * | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
| US7910661B2 (en) * | 2003-01-06 | 2011-03-22 | Nektar Therapeutics | Thiol-selective water-soluble polymer derivatives |
| GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ATE455174T1 (de) | 2003-09-23 | 2010-01-15 | Univ North Carolina | Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein |
| JP4855074B2 (ja) * | 2003-09-30 | 2012-01-18 | 一般財団法人化学及血清療法研究所 | 高純度血液凝固ｉｘ因子調製物およびその精製方法 |
| EP2272951B1 (en) | 2003-10-14 | 2014-07-23 | Baxter International Inc. | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| JP2008505119A (ja) * | 2004-06-30 | 2008-02-21 | ネクター セラピューティクス アラバマ，コーポレイション | 高分子−第ｉｘ因子部分の抱合体 |
| WO2006063292A1 (en) | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
| KR101310532B1 (ko) | 2005-02-28 | 2013-09-23 | 박스터 헬쓰케어 에스에이 | 비타민 ｋ 의존성 단백질 발현의 개선을 위한 비타민 ｋ에폭사이드 환원효소 소단위 １의 재조합 동시발현 |
| CA2601574C (en) | 2005-03-15 | 2014-12-02 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active vitamin k-dependent proteins |
| US20080255026A1 (en) * | 2005-05-25 | 2008-10-16 | Glycopegylated Factor 1X | Glycopegylated Factor Ix |
| WO2007126808A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc | Pegylated factor viii |
| AU2007253264A1 (en) * | 2006-05-24 | 2007-11-29 | Novo Nordisk Health Care Ag | Factor IX analogues having prolonged in vivo half life |
| JP5737821B2 (ja) * | 2006-08-17 | 2015-06-17 | 一夫 大橋 | 血友病ｂ治療剤及びその製造方法 |
-
2009
- 2009-04-24 KR KR1020107026368A patent/KR20110016440A/ko not_active Ceased
- 2009-04-24 CA CA2722169A patent/CA2722169A1/en not_active Abandoned
- 2009-04-24 EP EP09734192.9A patent/EP2280734B1/en not_active Not-in-force
- 2009-04-24 AU AU2009239641A patent/AU2009239641B2/en not_active Ceased
- 2009-04-24 BR BRPI0911350A patent/BRPI0911350A2/pt not_active IP Right Cessation
- 2009-04-24 UA UAA201013989A patent/UA101497C2/ru unknown
- 2009-04-24 RU RU2010147813/15A patent/RU2496521C2/ru not_active IP Right Cessation
- 2009-04-24 JP JP2011505616A patent/JP2011519833A/ja active Pending
- 2009-04-24 MX MX2010011672A patent/MX2010011672A/es active IP Right Grant
- 2009-04-24 ES ES09734192.9T patent/ES2466340T3/es active Active
- 2009-04-24 CN CN200980119877XA patent/CN102046205A/zh active Pending
- 2009-04-24 NZ NZ588854A patent/NZ588854A/en not_active IP Right Cessation
- 2009-04-24 US US12/989,555 patent/US20110183906A1/en not_active Abandoned
- 2009-04-24 MY MYPI2010004993A patent/MY158228A/en unknown
- 2009-04-24 WO PCT/IB2009/005763 patent/WO2009130602A2/en not_active Ceased
- 2009-04-24 DK DK09734192.9T patent/DK2280734T3/da active
-
2010
- 2010-10-22 NI NI201000177A patent/NI201000177A/es unknown
- 2010-10-22 ZA ZA2010/07559A patent/ZA201007559B/en unknown
- 2010-10-24 IL IL208908A patent/IL208908A0/en unknown
- 2010-10-27 CR CR11763A patent/CR11763A/es not_active Application Discontinuation
- 2010-11-24 CO CO10147494A patent/CO6300965A2/es not_active Application Discontinuation
- 2010-11-24 EC EC2010010632A patent/ECSP10010632A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013525414A5 (enExample) | ||
| RU2010147813A (ru) | Конъюгаты фактора ix с увеличенным временем полужизни | |
| CA2796870A1 (en) | Conjugated blood coagulation factor viia | |
| RU2012144555A (ru) | Конъюгированный фактор свертывания крови viii | |
| US12214044B2 (en) | Factor VIII zwitterionic polymer conjugates | |
| JP7014844B2 (ja) | オキシム連結のための求核触媒 | |
| JP2020514300A5 (enExample) | ||
| BR112020019639A2 (pt) | Conjugados de il-2 | |
| JP2014040441A5 (enExample) | ||
| JP2008542285A5 (enExample) | ||
| Hu et al. | In situ growth of a C-terminal interferon-alpha conjugate of a phospholipid polymer that outperforms PEGASYS in cancer therapy | |
| JP6004449B2 (ja) | トリブロックコポリマー及びその使用 | |
| RU2447083C1 (ru) | НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ | |
| JP7046321B2 (ja) | 修飾されたスチレン－無水マレイン酸共重合体及びその使用 | |
| JP2011507913A5 (enExample) | ||
| EA019345B1 (ru) | Композиции, содержащие конъюгаты пэг-интерферон-альфа и рафинозу в качестве криопротектора | |
| JP6253008B2 (ja) | 高分子化ホウ素化合物及びその使用 | |
| CN102153643B (zh) | 粒细胞集落形成刺激因子(g-csf)的突变体及其化学缀合多肽 | |
| CN1235939C (zh) | 靶向亲水性聚合物、及其与干扰素的结合物以及包含该结合物的药物组合物 | |
| US8329191B2 (en) | Three-branched polyethylene glycol-G-CSF conjugate | |
| US20170079928A1 (en) | Copolymers of formula (i) and uses | |
| RU2597795C2 (ru) | Ингибитор скопления жидкости в полостях организма | |
| JP2010536858A5 (enExample) | ||
| WO2021124266A1 (en) | Pegylation of a trail ligand | |
| HK40043414A (en) | Zwitterionic polymers for use as conjugates with factor viii |